BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2022 11:52:44 AM | Browse: 178 | Download: 308
 |
Received |
|
2022-04-03 13:52 |
|
Peer-Review Started |
|
2022-04-03 13:54 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-05-12 01:53 |
|
Revised |
|
2022-05-17 09:12 |
|
Second Decision |
|
2022-08-11 03:01 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-08-15 19:41 |
|
Articles in Press |
|
2022-08-15 19:41 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-07-15 16:59 |
|
Typeset the Manuscript |
|
2022-08-30 19:41 |
|
Publish the Manuscript Online |
|
2022-09-16 11:52 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhong-Hui Li, yinjie ma, zonghang jia, yueyan weng, ping zhang, shijie zhu and Fang Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fang Wang, MD, Chief Doctor, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Road, Beijing, Beijing 100102, China. wf074500@163.com |
| Key Words |
Metastatic pancreatic cancer; Gemcitabine; Nab-paclitaxel; Novel targeted agent; Survival |
| Core Tip |
Gemcitabine plus nab-paclitaxel (GA) is a commonly used first-line treatment regimen for metastatic pancreatic cancer, and many studies will add a novel targeted agent to this regimen to improve patient survival. However, the clinical effectiveness of GA is more controversial. We conducted a meta-analysis to compare the effectiveness and safety of GA combined with a targeted agent regimen and GA regimen. |
| Publish Date |
2022-09-16 11:52 |
| Citation |
Li ZH, Ma YJ, Jia ZH, Weng YY, Zhang P, Zhu SJ, Wang F. Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer. World J Clin Cases 2022; 10(27): 9703-9713 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i27/9703.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i27.9703 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
